Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Mimicking the Bone Extracellular Matrix through a Calcium Phosphate-Containing Thiol-Ene Cross-Linked Gelatin Composite.

Parmentier L., D'Haese S., Van der Meeren L., Szabó A., Skirtach AG., Dmitriev RI.

Laboratory Study on Face & Skin, published in Biomacromolecules (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Biomacromolecules (2024)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
39680045
DOI
10.1021/acs.biomac.4c01182
Citations
1

Abstract (original English)

Hydroxyapatite (HAP) and amorphous calcium phosphate (ACP) nanoparticles were incorporated into a thiol-ene clickable gelatin network to elucidate to what extent osteogenic differentiation of human dental pulp- and adipose-derived stem cells (HDPSCs/HASCs) could be further boosted. ACP nanoparticles increased the specific surface area by 23% and reduced the density by 13% while maintaining a comparable particle size (ACP: 25 ± 3 nm; HAP: 27 ± 3 nm). Overall, the incorporation of ceramic nanoparticles did not significantly alter the mechanical properties of the ceramic-containing composites compared to the unsubstituted thiol-ene network. ACP nanoparticles at high concentrations promoted a 21-day osteogenic response in HASCs (72.09 ± 20.20 ng Ca 2+ /ng DNA) comparable to HDPSCs, with the latter showing high calcium production irrespective of the ceramic content (78.45 ± 10.87 ng Ca 2+ /ng DNA), suggesting that the provided cues must be optimized according to the investigated cell type toward a cell-interactive coating application stimulating osteogenesis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansCalcium PhosphatesGelatinOsteogenesisExtracellular MatrixStem CellsDurapatiteCell DifferentiationNanoparticlesDental Pulp

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research